Cargando…

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays

Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment of thromboembolic diseases. However, these agents are associated with limitations, such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douxfils, Jonathan, Tamigniau, Anne, Chatelain, Bernard, Goffinet, Catherine, Dogné, Jean-Michel, Mullier, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351835/ https://www.ncbi.nlm.nih.gov/pubmed/25750588 http://dx.doi.org/10.1186/1477-9560-12-24

Ejemplares similares

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations
por: Douxfils, Jonathan, et al.
Publicado: (2015)

Perioperative management of patients on direct oral anticoagulants
por: Dubois, Virginie, et al.
Publicado: (2017)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
por: Hardy, M., et al.
Publicado: (2020)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014)

Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles
por: Gheldof, Damien, et al.
Publicado: (2013)

The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review
por: Devalet, Bérangère, et al.
Publicado: (2014)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles
por: Devalet, Bérangère, et al.
Publicado: (2019)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data
por: Hardy, Michaël, et al.
Publicado: (2020)

Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation
por: Tosetto, Alberto, et al.
Publicado: (2015)

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study
por: Hardy, Michaël, et al.
Publicado: (2021)

Case report: Application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus
por: Zou, Man, et al.
Publicado: (2022)

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis
por: Haguet, Hélène, et al.
Publicado: (2020)

Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests
por: Lessire, Sarah, et al.
Publicado: (2016)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review
por: Minet, Valentine, et al.
Publicado: (2017)

Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices and Impedance Aggregometry): A Systematic Study with Blood from Healthy Volunteers
por: Hardy, Michael, et al.
Publicado: (2020)

Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping-mode AFM and liquid Peak Force AFM
por: Hardij, Julie, et al.
Publicado: (2013)

NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
por: Gillot, Constant, et al.
Publicado: (2021)

Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer
por: Bouvy, Céline, et al.
Publicado: (2014)

Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients
por: Douxfils, Jonathan, et al.
Publicado: (2021)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
por: van den Heuvel, J. M., et al.
Publicado: (2018)

Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry
por: Jacqmin, Hugues, et al.
Publicado: (2020)

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
por: Favresse, Julien, et al.
Publicado: (2021)

Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review
por: Bareille, Marion, et al.
Publicado: (2021)

Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome
por: Gillot, Constant, et al.
Publicado: (2022)

Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults—Ineffectiveness of Oral Anticoagulation Treatment with VKA
por: Panisello-Tafalla, Anna, et al.
Publicado: (2015)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation
por: Mani, Helen, et al.
Publicado: (2015)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Antithrombotic therapy after mitral valve repair: VKA or aspirin?
por: van der Wall, Sake J., et al.
Publicado: (2018)

Thrombodynamics—A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment
por: Balandina, Anna N., et al.
Publicado: (2018)

Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis
por: Grover, Steven P., et al.
Publicado: (2022)

Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system
por: Bareille, Marion, et al.
Publicado: (2022)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls
por: Evrard, Jonathan, et al.
Publicado: (2022)

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
por: Morimont, Laure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j681581gav50p67fi1gnvqgjgv